Overview Request Sample Pages Request Customization Download PDF
You are viewing: China Veterinary Monoclonal Antibodies Market analysis

The China Veterinary Monoclonal Antibodies Market was valued at $30.29 Million in 2025 and projected to reach to $52.2 Million by 2030, representing a compound annual growth rate of 11.5%. China's veterinary monoclonal antibodies market is positioned for sustained growth through 2030, driven by modernization of animal agriculture and rising pet ownership in urban regions.

China Veterinary Monoclonal Antibodies Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

China Veterinary Monoclonal Antibodies Market Trends and Insights

  • This growth trajectory reflects China's increasing investment in animal health infrastructure and rising demand for advanced therapeutic solutions in livestock and companion animal care.
  • China's market expansion is driven by growing awareness of immunotherapy benefits among veterinarians and pet owners, coupled with regulatory support for innovative veterinary biologics. The 11.5% compound annual growth rate in China underscores the country's strategic focus on modernizing its veterinary pharmaceutical sector.
  • China's market is benefiting from rapid urbanization, increased pet ownership, and substantial government initiatives to enhance food security through improved animal health management.
  • By 2030, China is expected to solidify its position as a key regional hub for veterinary monoclonal antibody development and commercialization, supported by expanding manufacturing capabilities and clinical research infrastructure..

Key Market Statistics

  • CAGR (2025-2030) 11.5% CAGR
  • Market Size, 2025 ~USD 30.29 Million
  • Forecast, 2030 ~USD 52.2 Million
  • Country China

China Veterinary Monoclonal Antibodies Market Overview

Market Valuation Growth :

China's veterinary monoclonal antibodies market is valued at $30.29 million in 2025, with projections reaching $52.20 million by 2030, representing a robust 11.5% CAGR over the forecast period.

Rising Animal Health Investment :

China is significantly increasing investment in animal health infrastructure, driven by expanding livestock production and growing companion animal ownership in urban centers across major cities.

Therapeutic Demand Expansion :

Growing demand for advanced therapeutic solutions in both livestock and companion animal care is accelerating adoption of monoclonal antibody treatments in China's veterinary sector.

Regulatory Framework Development :

China's strengthening regulatory environment for veterinary biologics and increased government support for animal disease prevention are creating favorable conditions for market expansion.

China Veterinary Monoclonal Antibodies Market Dynamics

  • The country's focus on food security and animal disease control is spurring adoption of innovative therapeutic solutions.
  • Increasing collaboration between domestic pharmaceutical companies and international partners is accelerating product development and market penetration.
  • Government initiatives supporting veterinary innovation and biosecurity standards will further strengthen market dynamics, making China a key growth engine in the Asia-Pacific veterinary therapeutics landscape..

Related Ecosystem

Animal Health

Top Technologies
  • Polymerase Chain Reaction (PCR) Tests
  • Porcine
  • Immunodiagnostics
  • Lateral Flow Assays
  • Microarrays
Top Companies
  • Zoetis Inc.
  • Patterson Companies, Inc.
  • Virbac
  • Elanco Animal Health Incorporated
  • BOEHRINGER INGELHEIM GMBH

    Key Takeaways

    • China's veterinary monoclonal antibodies market is valued at $30.29 million in 2025 and will grow to $52.20 million by 2030, representing an 11.5% CAGR.
    • China's market growth is driven by rising pet ownership, urbanization, and government support for advanced animal health therapeutics.
    • China is emerging as a regional manufacturing and innovation hub for veterinary immunotherapy solutions in Asia Pacific.
    • China's regulatory environment is increasingly favorable for monoclonal antibody approvals, accelerating market entry for new therapies.

    Veterinary Monoclonal Antibodies Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment BEDINVETMAB (LIBRELA) (Product)
    Forecast Period 2025-2030
    Growth Rate CAGR of 12.4% from 2025 to 2030
    Largest Segment SUBCUTANEOUS ROUTE OF ADMINISTRATION (Route Of Administration)
    Market Size Base Year (Billions) ~USD 1.71 (2025)
    Revenue Forecast (Billions) ~USD 3.06 (2030)
    Segments Covered Animal Type, Product, Route Of Administration, Therapy Area, End User, Animal Type 2023-2030

    China Veterinary Monoclonal Antibodies Market Report Segmentation

    6 segment dimensions are covered across the global market.

    By Animal Type

    • Canines
    • Felines
    • Other Animal Types
    • Other Animals

    By Product

    • Bedinvetmab (Librela)
    • Canine Parvovirus Monoclonal Antibody (Cpma)
    • Frunevetmab (Solensia)
    • Gilvetmab
    • Lokivetmab (Cytopoint)
    • Other Products

    By Route Of Administration

    • Intravenous (Iv) Route Of Administration
    • Intravenous Route Of Administration
    • Oral Route Of Administration
    • Subcutaneous (Sc) Route Of Administration
    • Subcutaneous Route Of Administration

    By Therapy Area

    • Dermatology
    • Infectious Diseases
    • Oncology
    • Other Therapy Areas
    • Pain Management

    By End User

    • Other End Users
    • Veterinary Clinics
    • Veterinary Hospitals/ Specialty Centers
    • Veterinary Hospitals/Specialty Clinics
    • Veterinary Research & Academic Institutes

    By Animal Type 2023-2030

    • Canines
    • Felines
    • Other Animals

    CHINA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030

    Segment2023202420252026202820292030CAGR (%)
    OTHER END USERS2.282.452.642.853.323.593.898
    VETERINARY CLINICS10.0711.2912.6814.2417.9920.2322.7912.4
    VETERINARY HOSPITALS/SPECIALTY CLINICS11.4912.7514.1815.7819.5521.7924.3111.4
    VETERINARY RESEARCH & ACADEMIC INSTITUTES2.032.232.442.693.243.573.939.9
    TOTAL25.8728.7231.9535.5544.1149.1854.9211.4

    Target Audience

    • Veterinary Pharmaceutical Companies : Manufacturers and distributors need China-specific market intelligence to develop localized product strategies, identify distribution partnerships, and capitalize on the 11.5% CAGR growth opportunity.
    • Investment & Private Equity Firms : Investors evaluating opportunities in China's animal health sector require detailed market sizing, growth projections, and competitive landscape analysis to support due diligence and portfolio decisions.
    • Livestock & Companion Animal Producers : Large-scale animal producers and veterinary clinics need market insights to understand therapeutic innovation trends and make informed procurement decisions for monoclonal antibody treatments.
    • Government & Regulatory Bodies : Chinese agricultural and health authorities require market data to inform policy development, biosecurity standards, and strategic planning for animal disease prevention and food security initiatives.
    • Market Research & Consulting Firms : Research organizations and consultants need verified China market data to support client advisory services, competitive benchmarking, and strategic recommendations in the veterinary therapeutics sector.

    Reasons to Buy this Report

    • Market Size & Growth Validation : Obtain precise valuation data for China's veterinary monoclonal antibodies market with verified CAGR of 11.5%, enabling accurate financial forecasting and investment decision-making for the 2025-2030 period.
    • China-Specific Growth Drivers : Understand unique market dynamics specific to China including livestock expansion, companion animal trends, and government animal health initiatives that differentiate this market from global trends.
    • Competitive Positioning Strategy : Develop targeted market entry and expansion strategies by analyzing China's veterinary monoclonal antibodies landscape, regulatory environment, and key growth opportunities in livestock and companion animal segments.
    • Investment & Partnership Opportunities : Identify high-potential investment and partnership opportunities within China's rapidly expanding animal health infrastructure and therapeutic innovation ecosystem.
    • Risk Mitigation & Forecasting : Leverage comprehensive China market analysis to mitigate risks, validate business assumptions, and create data-driven forecasts for product launches and market expansion initiatives.

    Frequently asked questions

    What is the current market size of veterinary monoclonal antibodies in China?

    China's veterinary monoclonal antibodies market was valued at $30.29 million in 2025 and is projected to reach $52.20 million by 2030.

    What is the expected growth rate for China's veterinary monoclonal antibodies market?

    China's market is expected to grow at a compound annual growth rate (CAGR) of 11.5% from 2025 to 2030.

    What factors are driving growth in China's veterinary monoclonal antibodies market?

    Key drivers in China include rising pet ownership, rapid urbanization, government initiatives for animal health improvement, and increasing veterinary awareness of immunotherapy benefits.

    Which animal segments are most significant in China's veterinary monoclonal antibodies market?

    China's market serves both companion animals (pets) and livestock, with growing demand across both segments driven by urbanization and food security priorities.

    How does China's market compare to the global veterinary monoclonal antibodies market?

    China's 11.5% CAGR is slightly below the global average of 12.4%, but China represents a critical growth market within Asia Pacific with substantial expansion potential.

    RESEARCH METHODOLOGY

    This study involved the extensive use of both primary and secondary sources. The research process involved evaluating various factors affecting the industry to identify the segmentation, industry trends, key players, competitive landscape, market dynamics, and growth strategies.

    Secondary Research

    In the secondary research process, various secondary sources were referred to, including directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect valuable information for an extensive, technical, market-oriented, and commercial study of the veterinary monoclonal antibodies market. It was also used to obtain information about the key players, market classification & segmentation according to industry trends to the bottommost level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

    Primary Research

    In the primary research process, various primary sources from the supply and demand sides were interviewed to obtain critical qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, vice presidents, chairpersons, chief executive officers, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the veterinary monoclonal antibodies market. Primary sources from the demand side include professionals from veterinary hospitals and clinics, academic & research institutes, and pet owners.

    Breakdown of primary interviews

    Veterinary Monoclonal Antibodies Market

    Note: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = < USD 1.00 billion.

    Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The total size of the veterinary monoclonal antibodies market was determined after data triangulation from two approaches, as mentioned below. After each approach, the weighted average of these approaches was taken based on the level of assumptions used in each approach.

    Veterinary Monoclonal Antibodies Market

    Data Triangulation

    After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

    Market Definition

    Veterinary monoclonal antibodies are laboratory-produced antibodies designed to target specific antigens in animals, offering precise treatment for conditions like atopic dermatitis, osteoarthritis, and infectious diseases. These species-specific biologics are engineered to work effectively in the immune systems of dogs, cats, or livestock. They represent a significant advancement over traditional drugs by providing targeted therapy with fewer side effects.

    Stakeholders

    • Veterinary monoclonal antibody manufacturers
    • Animal healthcare product manufacturers
    • Veterinary monoclonal antibody distributors and wholesalers
    • Animal welfare associations
    • Veterinary clinics and care centers
    • Research and consulting firms
    • Veterinary R&D organizations
    • Contract research organizations
    • Contract manufacturing organizations
    • Venture capitalists

    Report Objectives

    • To define, describe, and forecast the veterinary monoclonal antibodies market by animal type, product, therapy area, route of administration, end user, and region
    • To identify and analyze key drivers, restraints, opportunities, and challenges influencing market growth
    • To strategically analyze the regulatory scenario, value chain analysis, supply chain analysis, Porter’s Five Forces analysis, ecosystem analysis, trade analysis, pricing analysis, patent analysis, impact of AI, case study analysis, adjacent market analysis, unmet needs/end user expectations, and trends and disruptions impacting customer business in the market
    • To analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall market
    • To analyze opportunities for stakeholders and provide details of the competitive landscape for key players
    • To strategically profile key players in this market and comprehensively analyze their market shares and core competencies
    • To track and analyze competitive developments such as product launches and approvals, partnerships, and expansions in the market

    Get the Full Veterinary Monoclonal Antibodies Market Report

    Full forecast, segment splits, and company analysis for all Veterinary Monoclonal Antibodies Market.

    Download Sample Pages Buy Report

    METHODOLOGY

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    Cite this Research
    DMCA.com Protection Status